DPP4 and diabetes mellitus: The differences between Poland and other countries were observed in the adoption of new antidiabetic drugs, e.g. in 2012 the share of DPP-4 inhibitors in the diabetes medication market amounted to approx. 10% in US and UK [14, 15], and only 0.003% in Poland.